Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$756.38 -0.9%	$649.73	$510.05 ▼ $779.03	$46.29B	0.41	350,555 shs	339,273 shs
BGNE BeiGene		$194.32	$154.43 ▼ $248.16	$18.03B	0.57	342,033 shs	331,608 shs
ONC BeOne Medicines	$324.34 -3.4%	$300.22	$170.99 ▼ $351.27	$35.55B	0.21	343,066 shs	274,640 shs
TAK Takeda Pharmaceutical	$15.11 -1.5%	$14.81	$12.80 ▼ $15.69	$48.08B	0.22	3.03 million shs	2.82 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	+0.75%	+15.68%	+37.22%	+40.59%
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	-6.94%
ONC BeOne Medicines	0.00%	-5.11%	+0.93%	+22.66%	+32,433,999,900.00%
TAK Takeda Pharmaceutical	0.00%	-1.85%	+0.80%	+0.30%	+2.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$756.38 -0.9%	$649.73	$510.05 ▼ $779.03	$46.29B	0.41	350,555 shs	339,273 shs
BGNE BeiGene		$194.32	$154.43 ▼ $248.16	$18.03B	0.57	342,033 shs	331,608 shs
ONC BeOne Medicines	$324.34 -3.4%	$300.22	$170.99 ▼ $351.27	$35.55B	0.21	343,066 shs	274,640 shs
TAK Takeda Pharmaceutical	$15.11 -1.5%	$14.81	$12.80 ▼ $15.69	$48.08B	0.22	3.03 million shs	2.82 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	+0.75%	+15.68%	+37.22%	+40.59%
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	-6.94%
ONC BeOne Medicines	0.00%	-5.11%	+0.93%	+22.66%	+32,433,999,900.00%
TAK Takeda Pharmaceutical	0.00%	-1.85%	+0.80%	+0.30%	+2.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.04	Buy	$772.84	2.18% Upside
BGNE BeiGene	3.00	Buy	$270.75	∞ Upside
ONC BeOne Medicines	3.00	Buy	$330.89	2.02% Upside
TAK Takeda Pharmaceutical	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest BGNE, TAK, ARGX, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2025	ARGX argenex	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
9/2/2025	ARGX argenex	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$880.00 ➝ $887.00
8/26/2025	ARGX argenex	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$818.00
8/26/2025	ARGX argenex	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$750.00 ➝ $820.00
8/25/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$800.00
8/25/2025	ARGX argenex	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$850.00
8/21/2025	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/7/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$349.00 ➝ $364.00
8/7/2025	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$350.00 ➝ $365.00
8/4/2025	ARGX argenex	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$775.00 ➝ $830.00
8/1/2025	ARGX argenex	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$700.00 ➝ $766.00

(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	20.55	$2.97 per share	254.63	$90.49 per share	8.36
BGNE BeiGene	$3.32B	0.00	N/A	N/A	$37.10 per share	0.00
ONC BeOne Medicines	$3.81B	9.33	N/A	N/A	$34.10 per share	9.51
TAK Takeda Pharmaceutical	$30.09B	1.60	$3.18 per share	4.75	$14.39 per share	1.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$19.50	38.79	69.71	0.80	40.98%	21.06%	18.25%	10/30/2025 (Estimated)
BGNE BeiGene	-$881.71M	-$8.24	N/A	N/A	N/A	-25.94%	-25.12%	-14.95%	N/A
ONC BeOne Medicines	-$644.79M	-$1.73	N/A	456.82	N/A	-3.89%	-1.22%	-0.72%	N/A
TAK Takeda Pharmaceutical	$712.33M	$0.30	50.37	9.16	N/A	3.20%	10.50%	5.10%	10/30/2025 (Estimated)

Latest BGNE, TAK, ARGX, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ONC BeOne Medicines	$0.48	$0.84	+$0.36	$0.84	$1.24 billion	$1.32 billion
7/31/2025	Q2 2025	ARGX argenex	$2.84	$3.74	+$0.90	$3.74	$776.82 million	$866.79 million
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	$0.52	+$0.05	$0.27	$7.96 billion	$7.45 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.55	3.64%	N/A	183.33%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.60	5.27
BGNE BeiGene	0.05	1.93	1.72
ONC BeOne Medicines	0.04	1.95	1.72
TAK Takeda Pharmaceutical	0.60	1.16	0.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
BGNE BeiGene	48.55%
ONC BeOne Medicines	48.55%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
BGNE BeiGene	7.43%
ONC BeOne Medicines	6.62%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.20 million	59.71 million	Optionable
BGNE BeiGene	9,000	97.62 million	90.20 million	Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable

BGNE, TAK, ARGX, and ONC Headlines

Recent News About These Companies

Baird Financial Group Inc. Invests $276,000 in Takeda Pharmaceutical Co. $TAK

September 14 at 3:03 AM | marketbeat.com

Takeda poaches top Lilly exec; Maze soars on early PKU drug data

September 12 at 11:48 AM | biopharmadive.comB

Antibody Drug Conjugates Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Bristol Myers Squibb, GSK, MBrace therapeutics, Oxford Biotherapeutics ...

September 11, 2025 | theglobeandmail.com

Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

September 11, 2025 | pharmiweb.comP

Takeda Pharmaceutical (NYSE:TAK) Sets New 1-Year High - Should You Buy?

September 10, 2025 | marketbeat.com

CVS Sues Takeda, Bora Units Claiming Collusion on Reflux Drug

September 9, 2025 | news.bloomberglaw.comN

Nikkei ends lower on yen strength, profit-taking after crossing 44,000

September 9, 2025 | msn.com

Japan's Nikkei rises to 44,000 for first time on trade, spending optimism

September 9, 2025 | msn.com

Assessing Takeda Stock After Recent 6% Jump and New FDA Approval for HyQvia Expansion

September 9, 2025 | finance.yahoo.com

Takeda nears first therapy for root cause of narcolepsy

September 9, 2025 | japantimes.co.jpJ

Promising Phase 3 Results for Takeda’s Oveporexton Boost Buy Rating

September 9, 2025 | tipranks.com

Takeda Pharmaceutical Company Limited (TAK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

September 9, 2025 | seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Oveporexton (TAK-861) Investor Call On Phase 3 Narcolepsy Type 1 Data Presented At World Sleep 2025 (Transcript)

September 8, 2025 | seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Special Call - Slideshow

September 8, 2025 | seekingalpha.com

Takeda Nears First Therapy for Narcolepsy’s Root Cause

September 8, 2025 | bloomberg.com

Nomura Holdings Inc. Invests $338,000 in Takeda Pharmaceutical Co. $TAK

September 8, 2025 | marketbeat.com

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

September 8, 2025 | businesswire.com

Adage Capital Partners GP L.L.C. Invests $51.05 Million in Takeda Pharmaceutical Co. $TAK

September 6, 2025 | marketbeat.com

Invesco Ltd. Buys New Shares in Takeda Pharmaceutical Co. $TAK

September 6, 2025 | marketbeat.com

U.S. FDA Approves Expanded Indication for VONVENDIÂ® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

September 5, 2025 | businesswire.com

Graham Capital Management L.P. Buys New Stake in Takeda Pharmaceutical Co. $TAK

September 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BGNE, TAK, ARGX, and ONC Company Descriptions

argenex NASDAQ:ARGX

$756.38 -7.14 (-0.94%)

Closing price 09/12/2025 04:00 PM Eastern

Extended Trading

$762.80 +6.42 (+0.85%)

As of 07:13 AM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BeOne Medicines NASDAQ:ONC

$324.34 -11.33 (-3.38%)

As of 09/12/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Takeda Pharmaceutical NYSE:TAK

$15.11 -0.23 (-1.50%)

Closing price 09/12/2025 03:59 PM Eastern

Extended Trading

$15.00 -0.11 (-0.73%)

As of 07:18 AM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BGNE, TAK, ARGX, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BGNE, TAK, ARGX, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BGNE, TAK, ARGX, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BGNE, TAK, ARGX, and ONC Company Descriptions

argenex NASDAQ:ARGX

BeiGene NASDAQ:BGNE

BeOne Medicines NASDAQ:ONC

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BGNE, TAK, ARGX, and ONC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BGNE, TAK, ARGX, and ONC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BGNE, TAK, ARGX, and ONC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BGNE, TAK, ARGX, and ONC Company Descriptions

argenex NASDAQ:ARGX

BeiGene NASDAQ:BGNE

BeOne Medicines NASDAQ:ONC

Takeda Pharmaceutical NYSE:TAK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools